Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Liabilities and Shareholders Equity (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Liabilities and Shareholders Equity for 6 consecutive years, with $79.6 million as the latest value for Q3 2025.

  • Quarterly Liabilities and Shareholders Equity rose 1718.52% to $79.6 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $262.7 million through Dec 2025, up 113.82% year-over-year, with the annual reading at $98.6 million for FY2024, 579.69% up from the prior year.
  • Liabilities and Shareholders Equity for Q3 2025 was $79.6 million at Inhibikase Therapeutics, down from $88.9 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $98.6 million in Q4 2024, with the low at $4.4 million in Q3 2024.
  • Average Liabilities and Shareholders Equity over 5 years is $39.1 million, with a median of $28.6 million recorded in 2022.
  • The sharpest move saw Liabilities and Shareholders Equity crashed 75.52% in 2024, then skyrocketed 1718.52% in 2025.
  • Over 5 years, Liabilities and Shareholders Equity stood at $42.5 million in 2021, then plummeted by 41.28% to $24.9 million in 2022, then tumbled by 41.83% to $14.5 million in 2023, then soared by 579.69% to $98.6 million in 2024, then decreased by 19.28% to $79.6 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $79.6 million, $88.9 million, and $94.3 million for Q3 2025, Q2 2025, and Q1 2025 respectively.